NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

5415.50 -10.50 (-0.19%)

143.7K NSE+BSE Volume

NSE 25 Aug, 2025 3:31 PM (IST)

64,750.4

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

14 May 2022

5415.50

-0.19%

Alkem Labs (BUY): Q4 revenue in line; margin guidance weak

Buy: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q4 revenue of Rs 24.8bn broadly in line with our estimate; PAT reduced 55% to Rs 1.1bn on account of prior years' tax

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

07 Mar 2022

5415.50

-0.19%

India focused play and encouraging outlook bodes well

Buy: Alkem Laboratories Ltd.

Target

Motilal Oswal

After MNC Pharma and pure-play companies like ERIS, ALKEM has minimal exposure to the international business. It has multiple growth drivers over the next 12-18 months, despite a high base in the past 12 months, due to: a) a revival in Non-COVID therapies and better MR productivity (14% net addition over the past two years), b) sustained outperformance in Chronic...

ICICI Securities Limited upgraded Alkem Laboratories Ltd. to Buy with a price target of 6065.0 on 13 Aug, 2025.

Alkem Laboratories Ltd.

05 Feb 2022

5415.50

-0.19%

Alkem Labs (HOLD): Strong domestic growth; weak margins

Hold: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Robust traction in India formulations (+20% YoY) during Q3, partly offset by a 7% decline in US generic revenue

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

07 Jun 2021

5415.50

-0.19%

On growth path despite high base of past year

Buy: Alkem Laboratories Ltd.

Target

Motilal Oswal

It had a positive impact of higher offtake of COVID-19 associated drugs in the recent past. The reduction in COVID-19 cases, coinciding with seasonal change, bodes well for a pick-up in the performance of Acute therapies. Bunched-up ANDA launches over the next 12-15 months are expected to improve sales growth as well as profitability of the US business. We have tweaked our FY22E/FY23E EPS estimate by 2%/3% and continue to value ALKEM at 23x 12-months forward earnings to arrive at our TP of INR3,730. We remain positive on the back of robust growth in the DF segment and...

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

26 May 2021

5415.50

-0.19%

Alkem Labs (BUY): Poor US sales and inventory provision affect Q4

Buy: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Alkem Labs reported a below-expected Q4FY21 with +7%/4% YoY sales/EBITDA growth.

Alkem Laboratories L.. has an average target of 5540.67 from 3 brokers.

Alkem Laboratories Ltd.

20 May 2021

5415.50

-0.19%

Alkem Laboratories Ltd - Ready for the next leap!

Buy: Alkem Laboratories Ltd.

Monarch Networth Capital Limited

ALKEM LABORATORIES LTD (Alkem) is a dominant Acute focused player in the IPM with leadership in the AntiInfectives. Its strong brands and penetration in the Acute side has led to its superior performance in the IPM. Chronic segment likely to double in size every 3 years on the back of Cardiac and Anti-diabetes. Higher profit contribution from chronic portfolio, improving MR productivity and rising scale in US generics will drive margin expansion of ~430bps over FY20-23E. Alkem's margins expansion visibility, rich return ratios and improving business profile merits a better multiple. We thus value Alkem at INR 4,000 on 17.5x EV/EVITDA on FY23E which gives an upside of 35% from the CMP. At current valuation of 13x EV/EBITDA and 18x PER on FY23E. Key risks include NPPA actions on key products, adverse USFDA regulatory actions and delay in biosimilars....

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

12 Apr 2021

5415.50

-0.19%

Pick of the Week - Alkem Laboratories Limited

Buy: Alkem Laboratories Ltd.

Edelweiss

Alkem is the seventh-largest branded pharma company in India.

ICICI Securities Limited upgraded Alkem Laboratories Ltd. to Buy with a price target of 6065.0 on 13 Aug, 2025.

Alkem Laboratories Ltd.

07 Nov 2020

5415.50

-0.19%

Alkem Lab

Buy: Alkem Laboratories Ltd.

Target

Dolat Capital

Alkem reported an in-line 2Q driven by exports and speedy recovery in India. Despite an acute heavy portfolio, India formulations were flattish YoY, up 35% QoQ exhibiting a sharp recovery aided by double digit growth in trade generics. US ($84mn) was strong with 12% CC growth backed by new launches and market share gains. As marketing and promotional activities resume slowly in India (~70%), EBITDA margins came 120bps lower sequentially at 25.4%. However, with promotional activities resuming normalcy we expect 2H to report margins of 15-16%,...